- Men, Make Health Your Goal This Year
- Child Car Seat Safety Tip: Skip Puffy Winter Coats
- UK Prime Minister Says British COVID Variant May Be More Deadly
- FDA Approves First Once-a-Month HIV Therapy
- Half of Americans Still Not Wearing Masks When Out in Public: Poll
- For Maximum Effectiveness, De-Stress and Get Healthy Before Your COVID Shot
- AHA News: Anxiety Is Linked With Smoking – But How Is Still Hazy
- Biden Warns of 500,000 COVID Deaths by February
- Health Highlights: Jan. 22, 2021
- For Rising Number of People, Obesity Is a Literal Headache
Opsumit Approved for Pulmonary Arterial Hypertension
WEDNESDAY, Oct. 23Opsumit (macitentan) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a debilitating disease characterized by high blood pressure in the lung arteries.
Pulmonary hypertension causes the heart to overwork, which can limit exercise, cause shortness of breath and create the need for a lung transplant. Opsumit relaxes the lung arteries, decreasing blood pressure in the vessels, the FDA said in a news release.
The drug’s safety and effectiveness were evaluated in clinical studies involving 742 people. The medication was found effective in “delaying disease progression,” the agency said.
The most common side effects included anemia, cold-like symptoms, bronchitis, headache, flu and urinary tract infection.
Opsumit’s label includes a boxed warning that the medication could harm a developing fetus, so the drug should not be taken by pregnant women, the FDA said.
The drug is marketed by Actelion Pharmaceuticals US, based in San Francisco.
More information
To learn more about PAH, visit the U.S. National Heart, Lung and Blood Institute.
Source: HealthDay
